All Oncology News

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Craig Moskowitz, MD, discusses the role of PET imaging in the treatment of patients with Hodgkin lymphoma, weighs the pros and cons of A+AVD, and speaks to where future research is headed in the space.

Justin M. Watts, MD, sheds light on these promising agents and their impact in the space, discusses remaining challenges, and expresses his hope for an era where most patients with acute myeloid leukemia will be cured.

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Lurbinectedin as monotherapy was found to elicit responses in patients with relapsed small cell lung cancer, meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.

Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.

Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Childhood cancer is significantly underdiagnosed—especially in south Asia and sub-Saharan Africa—underscoring the need for stronger health systems and the expansion of universal health coverage, according to an analysis published in Lancet Oncology.

Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma.

Mario Sznol, MD, highlights recent advances made with immunotherapy in renal cell carcinoma and sheds light on what the future may hold.

Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm.

Thomas Powles, MBBS, MRCP, MD, highlights key takeaways from pivotal trials and discusses how they impact the ever-changing landscape of metastatic renal cell carcinoma.

The ongoing phase III JAVELIN Ovarian PARP 100 study, which was evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer, has been discontinued.

The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies.

FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.

Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.

Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.

The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.

Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.

Andre Goy, MD, MS, shares insight on the stratification of patients with mantle cell lymphoma and other molecular markers that are being applied towards optimal treatment decisions in this disease.

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

Saad Z. Usmani, MD, shares insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.